INNA-051

INNA-051

Clinical data
Routes of administration	Intranasal

INNA-051 is a COVID-19 vaccine candidate developed by Ena Respiratory.[1][2]

References

1. "INNA-051 intranasal safety and tolerability study". anzctr.org.au. 21 April 2021. ACTRN12621000607875p. Retrieved 20 May 2021.
2. Clinical trial number NCT05118763 for "Intranasal INNA-051 for Prevention of COVID-19 in Adults" at ClinicalTrials.gov